PCM
BLUE

Portolan Capital Management’s bluebird bio BLUE Stock Holding History

Portolan Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,863
Closed -$1.61M – 113
2016
Q2 		$1.61M Sell
2,863
-2,083
-42% -$1.18M 0.23% 98
2016
Q1 		$2.72M Buy
4,946
+722
+17% +$443K 0.36% 90
2015
Q4 		$3.51M Buy
+4,224
New +$4.22M 0.45% 83

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Portolan Capital Management's BLUE Position: Q3 2016 in Review

Portolan Capital Management sold out of bluebird bio (BLUE) in Q3 2016, closing a stake of 2,863 shares — an estimated $1.61M sold.

Portolan Capital Management first reported a position in BLUE in Q4 2015 and held it in 3 quarters. The position peaked at $3.51M in Q4 2015. 200 funds tracked by Wall St. Rank hold BLUE as of Q3 2016.

  • Portolan Capital Management reported no remaining bluebird bio position as of Q3 2016 after selling out during the quarter.
  • Portolan Capital Management sold 2,863 bluebird bio shares in Q3 2016, an estimated $1.61M.
  • Portolan Capital Management first reported a position in bluebird bio in Q4 2015 and held it in 3 quarters.
  • Portolan Capital Management's bluebird bio position peaked at $3.51M in Q4 2015.
  • 200 funds tracked by Wall St. Rank held bluebird bio as of Q3 2016.

Based on Portolan Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.